Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaniprevir + Peg-IFN + Ribavirin in Japanese Patients with Chronic Hepatitis C
NCT00880763Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of vaniprevir in hepatitis C virus infection, sponsored by Merck & Co.. Started Apr 2009; status: completed.
02
Drugs
vaniprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00880763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00880763.